<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420601</url>
  </required_header>
  <id_info>
    <org_study_id>B1771016</org_study_id>
    <nct_id>NCT01420601</nct_id>
  </id_info>
  <brief_title>Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
  <official_title>Torisel 25mg For Intravenous Drip Infusion Special Investigation - Survey On Long-term Use -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the safety of the long-term use of TORISEL 25 mg for Intravenous Drip Infusion
      particularly for the onset of interstitial lung disease from Weeks 25 to 96 after the start
      of administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Implemented as a Drug Use Investigation by Central Registration System
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2011</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (Responsive cases: CR, PR, PD, SD)</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The onset of interstitial lung disease in long-term use</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events in long-term use</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Temsirolimus</arm_group_label>
    <description>Among the cases registered and treated in the Special Investigation, All-case Survey of temsirolimus, those continuously treated with temsirolimus for more than 24 weeks will be included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>The usual adult dosage of this drug is 25 mg as temsirolimus once weekly by intravenous drip infusion for 30 to 60 minutes. The dosage may be appropriately reduced, depending on patient condition.</description>
    <arm_group_label>Temsirolimus</arm_group_label>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with Torisel (patients with metastatic and/or radically unresectable or
        advanced renal cell carcinoma).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated with Torisel (patients with metastatic and/or radically unresectable
             or advanced renal cell carcinoma).

          -  Among patients registered and treated in the Special Investigation, All-case Survey of
             Torisel, those continuously treated with Torisel for more than 24 weeks will be
             included.

        Exclusion Criteria:

          -  Patients not administered Torisel.

          -  Patients with a history of severe hypersensitivity to temsirolimus, sirolimus
             derivative, or any of their components and/or derivatives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kinki University Hospital</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1771016&amp;StudyName=Temsirolimus%20%28Torisel%29%20Special%20Investigation%20%28Regulatory%20Post%20Marketing%20Commitment%20Plan%29%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2011</study_first_posted>
  <last_update_submitted>April 2, 2017</last_update_submitted>
  <last_update_submitted_qc>April 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Torisel</keyword>
  <keyword>Long-term use</keyword>
  <keyword>Regulatory Post Marketing Commitment Plan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

